CIBC Asset Management Inc Acquires 128,992 Shares of Gilead Sciences, Inc. $GILD

CIBC Asset Management Inc lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 32.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 532,120 shares of the biopharmaceutical company’s stock after buying an additional 128,992 shares during the quarter. CIBC Asset Management Inc’s holdings in Gilead Sciences were worth $65,312,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in GILD. Ares Financial Consulting LLC bought a new position in shares of Gilead Sciences in the fourth quarter valued at about $28,000. Financial Consulate Inc. raised its holdings in shares of Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 109 shares during the last quarter. North Star Investment Management Corp. raised its position in Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 86 shares during the last quarter. BOCHK Asset Management Ltd acquired a new position in Gilead Sciences during the 4th quarter worth $31,000. Finally, Godfrey Financial Associates Inc. acquired a new position in Gilead Sciences during the 4th quarter worth $34,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $127.57 on Wednesday. The firm has a fifty day moving average of $135.10 and a two-hundred day moving average of $134.26. The stock has a market capitalization of $158.39 billion, a price-to-earnings ratio of 17.38 and a beta of 0.31. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is 44.69%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the sale, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at $22,907,973.57. This represents a 1.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider directly owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,000 shares of company stock valued at $9,047,570 in the last ninety days. 0.30% of the stock is owned by insiders.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in primary biliary cholangitis, showing statistically significant ALP normalization versus placebo after 52 weeks. This adds to investor optimism around its liver disease franchise and broader growth prospects. Article Title
• Positive Sentiment: Separate coverage highlighted additional favorable Livdelzi data, including long-term efficacy and safety findings and a post hoc analysis showing sustained normalization of a key liver marker in PBC patients. These results reinforce confidence in the drug’s commercial potential. Article Title Article Title
• Positive Sentiment: Royal Bank of Canada upgraded Gilead from hold to moderate buy, which can bolster sentiment by signaling improved analyst confidence in the stock’s outlook.
• Positive Sentiment: Cencora announced it will support U.S. distribution of Kite’s FDA-approved CAR-T therapies, Yescarta and Tecartus, helping ensure continued commercialization and access for an important Gilead unit. Article Title
• Neutral Sentiment: Gilead also has several upcoming and recent oncology presentations with Kite at ASCO and EHA, which keep the company in focus but do not yet provide a clear near-term financial read-through. Article Title
• Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan. While routine, insider selling can still weigh on sentiment for some investors. Article Title

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Morgan Stanley reduced their price objective on Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. Deutsche Bank Aktiengesellschaft upped their price objective on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Oppenheimer upped their price objective on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. TD Cowen upped their price objective on Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Finally, Daiwa Securities Group dropped their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Twenty-six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $156.93.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.